Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | 10% owner | January 09, 2020 | January 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date January 09, 2020 · Filed January 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,208,472 |
Ending reported balance
After 2020-01-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-09 · Grant · Acquired 777,635 · Balance 782,238 F1: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly-owned subsidiary of the Issuer. F2: These shares were received in exchange for: i) 571,428 shares of ArTara Sub common stock; and ii) 3,505,174 shares of ArTara Sub exchangeable common stock, in connection with the merger. Row 2 · 2020-01-09 · Grant · Acquired 1,426,234 · Balance 2,208,472 |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly-owned subsidiary of the Issuer.
F2: These shares were received in exchange for: i) 571,428 shares of ArTara Sub common stock; and ii) 3,505,174 shares of ArTara Sub exchangeable common stock, in connection with the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2020 Filed Jan 13, 2020 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 1,426,234 | $7.01 | $9,997,900.34 |
DisclosureSEC source: 0001209191-20-003219 · doc4.xml · nonDerivative · entry 2 Opaleye, L.P. · CIK 0001391634 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,208,472 Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 777,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-003219 · doc4.xml · nonDerivative · entry 1 Opaleye, L.P. · CIK 0001391634 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,238 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly-owned subsidiary of the Issuer. F2 · price: These shares were received in exchange for: i) 571,428 shares of ArTara Sub common stock; and ii) 3,505,174 shares of ArTara Sub exchangeable common stock, in connection with the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.